Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) can cause side effects that range from mild to serious. More common side effects include headache and ...

Fluticasone furoate, umeclidinium, vilanterol 100/62.5/25mcg, 200/62.5/25mcg; per inh; dry pwd for oral inhalation. Trelegy Ellipta is supplied as a disposable light grey and beige plastic inhaler ...

One of these new inhalers that contains a combination of long-acting medicines is called Trelegy Ellipta. It is the first inhaler that contains three medicines to treat asthma. You may hear this ...

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is a prescription drug used to treat COPD. With COPD, you have lung damage that worsens over time ...

So far Trelegy has been launched in 30 countries and continues to roll out, with recent approvals in Japan and China setting up launches in those big markets later this year.

New respiratory drugs Nucala (mepolizumab) for severe asthma and Advair follow-up Trelegy (fluticasone furoate, umeclidinium, and vilanterol) made a solid supporting cast in the three-month period.

GlaxoSmithKline plc GSK and partner Innoviva, Inc. INVA announced that the FDA has granted approval to its medicine Trelegy Ellipta for a new asthma indication. The FDA has approved the triple ...

RELATED: With latest data, can AstraZeneca's COPD triple combo rival Glaxo's Trelegy? AZ and GSK have long been locked in a tight fight in the respiratory field. But at least for three-drug COPD ...